Ahalf	Drug amount associated with half of the maximum adsorption capacity
ALAG	Delay of oral adsorption after oral intake
Amax	Maximum drug amount that can be adsorbed
ARDS	Acute respiratory distress syndrome
BAS	Basiliximab
CA	California
Ci	Inlet drug concentration
CL	Clearance
Co	Outlet drug concentration
CLmax	Maximum clearance
CPB	Cardiopulmonary bypass
CRRT	Continuous renal replacement therapy
CV	Coefficient of variation
CYA	Cyclosporin A
DAMPS	Damage associated molecular patterns
E	Elimination rate
ECC	Extracorporeal circulation
ECMO	Extracorporeal membrane oxygenation
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
Eq.	Equation
EVER	Everolimus
EVLP	Ex-vivo lung perfusion
F	Bioavailability
FL	Plasma/Serum flow through the adsorber
HPLC	high performance liquid chromatography
ID	Immunosuppressant drugs
IIVs	Interindividual Variabilities
KA	First order oral absorption rate
LC–MS/MS	Liquid Chromatography with tandem mass spectrometry
MMF	Mycophenolat Mofetil
MP	Methylprednisolone
OFV	Objective function value
PAMPS	Pathogen associated molecular patterns
PK	Pharmacokinetics
PRED	Prednisolone
Q	Intercompartmental clearance
RSE	Relative standard error
TAC	Tacrolimus
USA	United States of America
V	Volume of distribution
V1	Central volume of distribution
V2	Peripheral volume of distribution